- In April 2025, RadNet, a major diagnostic imaging provider, announced an all‑stock acquisition of iCAD (a breast-health AI leader), valuing the deal at approximately USD 103 million. The merger aims to accelerate RadNet’s AI-powered breast cancer screening and diagnostic capabilities by integrating iCAD’s ProFound Breast Health Suite into its DeepHealth portfolio
- In March 2025, CAD announced a strategic partnership with RamSoft to embed its ProFound AI Breast Health Suite into RamSoft’s RIS/PACS platform across North America. The integration, expanding to over 750 imaging sites (starting with Mammolink), enhances workflow efficiency and improves breast cancer detection rates
- In March 2025, At the European Congress of Radiology (ECR) 2025, iCAD presented clinical performance and new real‑world data for its ProFound AI Breast Health Suite. The showcase included AI‑powered modules for detection, density assessment, and risk evaluation, building on 20+ years of breast‑health innovation
- In March 2022, EDDA Technology entered into a formal collaboration with the Society of Interventional Oncology (SIO) for the ACCLAIM trial—a study evaluating microwave ablation with real-time 3D margin assessment for colorectal liver metastases—using its IQQA-BodyImaging software to ensure precise ablation margins during the procedure
- In November 2021, Fujifilm began clinical deployment of its REiLI AI platform, which incorporates tools for detecting intracranial hemorrhage in stroke patients and supporting breast cancer diagnosis using mammography and other imaging modalities
